ATLANTA, Dec. 1, 2011 /PRNewswire/ -- Arbor Pharmaceuticals announced today that it has filed its first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

RALEIGH, N.C., June 2 /PRNewswire/ -- Arbor Pharmaceuticals ("Arbor"), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched ZINOTIC ES as a new treatment option for Acute Otitis Externa (AOE).

RALEIGH, N.C., Feb.

RALEIGH, N.C., Jan. 7 /PRNewswire/ -- Arbor Pharmaceuticals ("Arbor"), an emerging specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company recently closed its Series A financing.

US-based Arbor Pharmaceuticals has entered into an agreement with Campbell University's Pharmaceutical Sciences Institute to develop Arbor's latest product, a pediatric treatment for ear infections.